Fundraising FoxXeris Pharmaceuticals
Austin, US · Delaware corporation · 1 known investors
Find your way into Xeris Pharmaceuticals
Sign up to see every warm intro you have to Xeris Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xeris Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SP
Steven PrestrelskiCo-founder
DB
Douglas BaumCo-founder
JK
John KinzellCo-founder
PS
Poul StrangeExecutive
Board
RF
Robert FaulkerBoard director
CM
Cary McNairBoard director
TS
Timothy SullivanBoard director
SB
Shane BrisbinBoard director
NP
Navneet PuriBoard director
JR
Jonathan RigbyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$82.3M disclosed across 3 rounds · 2014–2017
▶$30.1MraisedMay 2017 · 22 investors · PharmaceuticalsRule 506(b)
▶$30.1MraisedMay 2017 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul EdickExecutive Officer, Director
- Cary McNairDirector
- John ShannonExecutive Officer
- Robert FaulkerDirector
- Navneet PuriDirector
- Brad HuckabeeExecutive Officer
- Jonathan RigbyDirector
- Offering amount
- $45M
- Amount sold
- $30.1M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedDec 2016 · 48 investors · PharmaceuticalsRule 506(b)
▶$45MraisedDec 2016 · 48 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert FaulkerDirector
- Poul StrangeExecutive Officer
- Navneet PuriDirector
- Steven PrestrelskiExecutive Officer
- Cary McNairDirector
- Douglas BaumExecutive Officer, Director
- Jonathan RigbyDirector
- Offering amount
- $50M
- Amount sold
- $45M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.3MraisedSep 2014 · 56 investors · Other TechnologyRule 506(b)
▶$7.3MraisedSep 2014 · 56 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Yash SabharwalExecutive Officer
- John KinzellExecutive Officer, Director
- Timothy SullivanDirector
- Douglas BaumExecutive Officer, Director
- Shane BrisbinDirector
- Steven PrestrelskiExecutive Officer
- Offering amount
- $14.9M
- Amount sold
- $7.3M
- Minimum investment
- $25K
- Finders' fees
- $55.5K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Xeris Pharmaceuticals?
- Xeris Pharmaceuticals was founded by Steven Prestrelski, Douglas Baum, John Kinzell.
- Who are Xeris Pharmaceuticals's investors?
- Xeris Pharmaceuticals's investors include Bay City Capital.
- How much funding has Xeris Pharmaceuticals raised?
- Xeris Pharmaceuticals has disclosed $82.3M raised across 3 rounds.
- Where is Xeris Pharmaceuticals headquartered?
- Xeris Pharmaceuticals is headquartered in Austin, US.